Conference on 4th Annual Stability Testing Bharatbook
Conference on 4th Annual Stability Testing Bharatbook.com announces the inclusion of latest conference on "Conference on 4th Annual Stability Testing" 4th Annual Stability Testing Examining current challenges and exploring more cost-effective strategies. 22nd – 23rd November 2010, BSG Conference Centre, London, UK Key Speakers: Garry Scrivens, Senior Principal Scientist, Pfizer, David Elder, Externalization Director, GlaxoSmithKline, Ahmed Yasin, BioPharm Analytical & Formulation Research, GlaxoSmithKline, Dagmar Mohr, Group Head Analytical R&D and QC Biotech Products, Roche, Simona Bohanec, Head of Regulatory Analytics, Sandoz, Duu-Gong Wu, Executive Director, PharmaNet, Jan Jiskra, Project leader, Synthon, Jane Robinson, Principal Scientist, Biotherapeutics, National Institute for Biological Standards and Control, Conference Introduction 4th Annual Stability Testing 22nd - 23rd November 2010, London, UK Failing to conduct a proper stability testing can be very time consuming and costly for companies, and damaging to their reputation. The cost of taking NCE through the development stages can range anywhere between $800 million to $1.2 billion (source: Springer, 2009). It is therefore, important for companies to understand key factors affecting the stability profile of a potential product, and carry out an effective stability program. 4th Annual Stability Testing Conference will feature key industry experts who will aim to share their experiences and explore key themes, including criteria for product stability, challenges associated with specific product types (including biotechnology products). Attendees will gain latest insights into the regulations, risk management, as well as the application and limitations of stability test procedures. (http://www. bharatbook.com/detail.asp?id=144496&rt=Conference-on-4th-Annual-Stability-Testing.html) Why you should attend this conference: • Understand strategies to design and implement a compliant stability program. • Hear the latest regulations guidelines, including FDA and ICH requirements. • Examine when it is best to perform stability tests: at what stage in the lifecycle? • Debate the best approaches for data management of statistical data. • Understand the importance of risk assessment. • Review current methods used to reduce costs. file:///C|/Documents%20and%20Settings/user29/Desktop/...ference%20on%204th%20Annual%20Stability%20Testing.htm (1 of 6)7/27/2010 1:39:45 PM